Recent News

• 11.03.2026 - Denali Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
• 10.30.2026 - Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product
• 10.22.2026 - Denali Therapeutics to Report Third Quarter 2026 Financial Results and Business Highlights on November 3, 2026
• 08.06.2026 - Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
• 07.27.2026 - Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026
• 07.09.2026 - Denali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier
• 06.18.2026 - Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million
• 05.21.2026 - Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
• 05.07.2026 - Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
• 04.03.2026 - Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Recent Filings

• 11.03.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.03.2026 - EX-99.1 EX-99.1
• 11.03.2026 - 8-K Current report
• 09.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.04.2026 - 144 Report of proposed sale of securities
• 09.04.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 09.02.2026 - 144 Report of proposed sale of securities
• 09.01.2026 - 144 Report of proposed sale of securities
• 08.14.2026 - 4 Statement of changes in beneficial ownership of securities